OS in patients with the respective cytogenetically defined risk group separated according to day 16 blasts less than 10% versus 10% or more.

I indicates favorable cytogenetics and day 16 blasts fewer than 10% (n = 39, censored = 26; median, nr); II, favorable cytogenetics and day 16 blasts 10% or more (n = 6, censored = 5; median, nr); III, prognostically intermediate cytogenetics and day 16 blasts fewer than 10% (n = 136, censored = 64; median, 26 months); IV, prognostically intermediate cytogenetics and day 16 blasts 10% or more (n = 81, censored = 33; median, 12 months); V, unfavorable cytogenetics and day 16 blasts fewer than 10% (n = 30, censored = 10; median, 11 months); VI, unfavorable cytogenetics and day 16 blasts 10% or more (n = 29, censored = 7; median, 4 months). The level of significance of the respective differences according to fewer than 10% versus 10% or more day 16 blasts within the groups with favorable, prognostically intermediate, and unfavorable cytogenetics are ns,P = .00263 and P = .02095, respectively.